Status:
COMPLETED
Pharmacokinetics and Pharmacodynamics of Levobupivacaine During Continuous Caudal Epidural Analgesia in Newborns
Lead Sponsor:
University Hospital, Motol
Conditions:
Analgesia
Eligibility:
All Genders
1-5 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn about the pharmacokinetics of levobupivacaine in newborns during the continus caudal epidural analgesia. This type of analgesia is used for severly ill newb...
Eligibility Criteria
Inclusion
- Obtained informed consent of parent(s)/legal representative(s)
- Age younger than 45thweek of PMA
- Age older than 25thweek of PMA
- body weight (BW) more than 500g
- Previous or planned operation with great demand on POPM
- Other diseases demanding great POPM (even without any need of surgery)
- Vital functions of the patient will be stable and there will be no suspicion, that patient current condition might be worsen by insertion of c-CELA (every patient will be discussed with attending physician )
Exclusion
- Decline of informed consent by parent(s) legal representative
- Age older than 45thweek of PMA
- Age younger than 25th week of PMA
- body weight (BW) lower than 500g
- Congenital malformation of caudal part of spine ( spina bifida occulta , meningocele, meningomyelocele)
- Disease or congenital malformation significantly restricting liver functions (Elevation of liver enzymes more than twice above the physiological range of the corresponding PMA)
- Disease or congenital malformation significantly restricting kidney functions (Elevation of urea and creatinine enzymes more than twice above the physiological range of the corresponding PMA)
- Clinical condition, which doesn't long-term POPM
- Meningism
- Patients with proven withdrawal syndrome caused by opiate administration
- High risk of bleeding during insertion (coagulopathy) or known administrated anticoagulants which might be still active in the time of insertion of c-CELA
- Substantial anemia (under 90g/l), which could lead to blood transfusion due to blood drawing
- frequent blood tests associated with the treatment of the patient(with blood samples necessary for the purposes of the study together), which would exceed maximum
- any hemodynamically unstable condition (for example septic shock)
Key Trial Info
Start Date :
February 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 7 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06171295
Start Date
February 4 2021
End Date
July 7 2022
Last Update
December 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospital Motol
Prague, Czechia, 15006